Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joerg Wenzel

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
Frontiers in Immunology|January 28, 2021
Immunostimulatory Endogenous Nucleic Acids Perpetuate Interface Dermatitis-Translation of Pathogenic Fundamentals Into an <i>In Vitro</i> ModelChristine Braegelmann, Tanja Fetter, Dennis Niebel, et al.
The British Journal of Dermatology|July 17, 2025
Beneath the surface: Delineating the subtypes of Dowling-Degos diseaseSheetal Kumar, Damian J Ralser, Joerg Wenzel, et al.
Frontiers in Immunology|March 21, 2020
Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin LesionsTanja Fetter, Paul Smith, Tugce Guel, et al.
American Journal of Clinical Pathology|June 1, 2005
Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesionsJoerg Wenzel, Barbara Bekisch, Manfred Uerlich, et al.
Dermatology (Basel, Switzerland)|April 4, 2013
Real-time tissue elastography as promising diagnostic tool for diagnosis of lymph node metastases in patients with malignant melanoma: a prospective single-center experienceTorsten Hinz, Tobias Hoeller, Joerg Wenzel, et al.
Frontiers in Immunology|October 29, 2025
Anifrolumab has a direct immunoregulatory effect on inflamed keratinocytes: implications for the treatment of lupus erythematosus skin lesionsKsenia Kalyniuk, Tanja Fetter, Marie Grützbach, et al.
Dermatopathology (Basel, Switzerland)|October 26, 2021
Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 VaccinesDennis Niebel, Joerg Wenzel, Dagmar Wilsmann-Theis, et al.
Dermatopathology (Basel, Switzerland)|March 24, 2022
Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological VariationDennis Niebel, Dagmar Wilsmann-Theis, Thomas Bieber, et al.
The American Journal of Pathology|December 7, 2007
Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation?Marina Scheler, Joerg Wenzel, Thomas Tüting, et al.
Rheumatology International|July 25, 2003
Bullous lupus erythematosus in a patient with pre-existing dermatomyositisJoerg Wenzel, Dirk Bokemeyer, Dagmar Wilsmann, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Frontiers in Immunology|January 28, 2021
Immunostimulatory Endogenous Nucleic Acids Perpetuate Interface Dermatitis-Translation of Pathogenic Fundamentals Into an <i>In Vitro</i> ModelChristine Braegelmann, Tanja Fetter, Dennis Niebel, et al.
The British Journal of Dermatology|July 17, 2025
Beneath the surface: Delineating the subtypes of Dowling-Degos diseaseSheetal Kumar, Damian J Ralser, Joerg Wenzel, et al.
Frontiers in Immunology|March 21, 2020
Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin LesionsTanja Fetter, Paul Smith, Tugce Guel, et al.
American Journal of Clinical Pathology|June 1, 2005
Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesionsJoerg Wenzel, Barbara Bekisch, Manfred Uerlich, et al.
Dermatology (Basel, Switzerland)|April 4, 2013
Real-time tissue elastography as promising diagnostic tool for diagnosis of lymph node metastases in patients with malignant melanoma: a prospective single-center experienceTorsten Hinz, Tobias Hoeller, Joerg Wenzel, et al.
Frontiers in Immunology|October 29, 2025
Anifrolumab has a direct immunoregulatory effect on inflamed keratinocytes: implications for the treatment of lupus erythematosus skin lesionsKsenia Kalyniuk, Tanja Fetter, Marie Grützbach, et al.
Dermatopathology (Basel, Switzerland)|October 26, 2021
Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 VaccinesDennis Niebel, Joerg Wenzel, Dagmar Wilsmann-Theis, et al.
Dermatopathology (Basel, Switzerland)|March 24, 2022
Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological VariationDennis Niebel, Dagmar Wilsmann-Theis, Thomas Bieber, et al.
The American Journal of Pathology|December 7, 2007
Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation?Marina Scheler, Joerg Wenzel, Thomas Tüting, et al.
Rheumatology International|July 25, 2003
Bullous lupus erythematosus in a patient with pre-existing dermatomyositisJoerg Wenzel, Dirk Bokemeyer, Dagmar Wilsmann, et al.
Pageof 9